CJC-1295 is a lab-made peptide, a short chain of protein building blocks, studied for growth hormone release. Small human studies tested its longer-lasting form and measured hormones, not health benefits. It is coming soon to Promise.
Coming soon
You are on the list. We will email you when CJC-1295 becomes available — and nothing else. Joining is not a medical request, and no prescription has been issued.
That did not go through. Check the address and try again.
CJC-1295 is coming soon to Promise. Add your email and we'll let you know when visits open.
A licensed provider reviews every request; not everyone qualifies.
Every treatment gets its own online clinical questionnaire — your history, medications, and goals.
A real person goes through your history and takes the time to get it right before anything is decided.
If a treatment isn't right for your history, you'll hear that plainly. That review is the whole point.
Made for your prescription by a licensed U.S. pharmacy and shipped in temperature-safe packaging.
Your care team checks in after it arrives. Adjust with your provider, or cancel at any time.
CJC-1295 is easy to find online and hard to trust there. Promise works the way medicine is supposed to work — a clinician decides, a licensed pharmacy fills, and someone stays accountable to you.
Prescribed for you specifically, after a real look at your health history — never pulled off a shelf.
Your prescription is compounded for you by a licensed U.S. pharmacy — not a mystery vial from an unregulated website.
Temperature-safe shipping, follow-up check-ins, and a care team that answers — before and after your medication arrives.
CJC-1295 is studied for signaling the pituitary, the gland that releases growth hormone. Its design copies a natural signal rather than supplying growth hormone itself.
Published studies examined the form with DAC, an attachment that binds a blood protein. They measured hormones in healthy adults without establishing sleep, muscle or recovery benefits or long-term safety.
When visits open, a licensed provider will review your history and the evidence for your goal. They may request more information or decline to prescribe.
CJC-1295 is a lab-made peptide, a short chain of protein building blocks, studied for growth hormone release. Small human studies used its longer-lasting form and measured hormones. They did not establish better sleep, muscle gain or faster recovery.
CJC-1295 is coming soon to Promise — add me to the list.
It copies part of growth-hormone-releasing hormone, or GHRH, the body's signal to release growth hormone. Researchers started with the first 29 amino acids, the building blocks in a peptide, and changed four positions to resist breakdown. This makes it an analog: a copy with changes.
The signal reaches the pituitary, a small gland beneath the brain that releases growth hormone. The peptide does not supply growth hormone itself. That distinction explains its place among the compounds in Hormone & Organ Health.
The name alone leaves an important question unanswered. Two different molecules share it in common usage, and their evidence cannot be swapped.
DAC stands for drug affinity complex, an attachment that lets the peptide bind albumin, a protein in blood. That binding keeps the DAC form in circulation for days. This is the long-acting molecule used in the familiar human studies.
The label “without DAC” usually refers to modified GRF 1-29. It lacks the albumin-binding attachment and is commonly described as shorter acting. A precise human clearance time for that exact molecule has not been established. Giving it the DAC form's duration would turn a naming shortcut into a false fact.
Our guide to the no-DAC label explains the distinction further. These are different structures, not simply different strengths of the same preparation. A familiar name cannot tell you which evidence applies.
A 2006 paper by Teichman and colleagues reported two trials in healthy adults, with random assignment and placebo, an inactive comparison. They lasted 28 and 49 days. Researchers measured drug persistence, growth hormone and IGF-1, a growth signal affected by growth hormone. The DAC form produced sustained hormone changes; these were blood-test findings.
In a separate 2006 study by Ionescu and Frohman, researchers sampled blood overnight in healthy men. Pulses, or bursts of growth hormone release, remained detectable one week after the DAC form. Longer drug exposure did not mean that the gland stopped releasing pulses.
Neither study measured better sleep, muscle gain or recovery. Neither tested modified GRF 1-29 or a combination with ipamorelin. They also cannot settle safety over years. A hormone response is one research finding; how someone feels and functions needs its own study.
CJC-1295 is not FDA-approved, and no FDA-approved U.S. product contains it.
FDA's safety summary identifies serious adverse events associated with this compound, including a faster heart rate and systemic vasodilatory reactions, meaning blood vessels widen throughout the body. FDA also raises concerns about unwanted immune responses, impurities and difficulty confirming the exact ingredient. The agency describes the available clinical data as limited.
It entered 503A Category 2, FDA's group for compounding ingredients with significant safety concerns, in 2023. The nominations were later withdrawn. An advisory committee voted against adding it to the compounding ingredient list in December 2024. The FDA review history explains those separate events.
A licensed provider may still prescribe — that decision is between you and your doctor.
Sermorelin copies the active fragment of the natural hormone-release signal without the same substitutions. The sermorelin comparison explains why its simpler structure differs from the CJC family.
Tesamorelin has a deeper human trial record, including studies measuring abdominal fat in adults with HIV. That is a specific patient group and research question. The tesamorelin comparison explains why those findings do not establish a result for this compound.
The CJC-1295 / Ipamorelin blend, which Promise offers by prescription, adds a second peptide that signals a different receptor, a cell's receiving switch. Adding an ingredient changes what needs to be studied. Evidence for one ingredient cannot establish the blend's effects, and a combination is not automatically the better choice.
When visits open, the process will begin with an intake questionnaire written for this compound. It will cover your health history, medicines and reason for asking. A provider may request lab work before deciding.
A licensed provider will read your answers and decide whether to prescribe.
If prescribed, the prescription will name the exact form, with or without DAC. A licensed U.S. pharmacy will compound and dispense the medication, meaning prepare it for an individual prescription.
It will be a compounded medication, which is different from an FDA-approved product: the formulation Promise will offer is not FDA-approved. Compounded medications are not reviewed by the FDA for safety, effectiveness, or quality.
Your provider sets any protocol; Promise does not publish dosing. Follow-up check-ins from your care team will keep the plan under review. That process provides someone responsible for clinical decisions while the limits of the evidence remain visible.
CJC-1295 is a lab-made peptide, a short chain of protein building blocks, studied for growth hormone release. It copies part of the body's natural hormone-release signal. The name is used for two forms: one with a blood-protein attachment called DAC, and one without it. The familiar human studies tested the longer-lasting DAC form and measured hormone levels, not health benefits.
Yes. When visits open, CJC-1295 will be prescribed by a licensed provider after a review of your health history and compounded for you by a licensed U.S. pharmacy. It will not be a product labeled for laboratory use. A prescription will be written only if the provider determines it is appropriate for you.
Starting a visit will not guarantee a prescription. Once visits open, a licensed provider will review your health history, current medicines and reason for asking. They may request more information or decline. The review is a medical decision; joining the list only means you'll hear when visits open.
No. CJC-1295 is not FDA-approved, and no FDA-approved product contains it. The formulation Promise will offer is a compounded medication, prepared by a pharmacy for an individual prescription. Compounded medications are not reviewed by the FDA for safety, effectiveness, or quality. A provider's review does not change that status.
Not yet. CJC-1295 is coming soon to Promise — add me to the list on this page and we'll email you when visits open. The list is for a notification; it does not start a medical visit or issue a prescription. The future visit will include a licensed provider's review before any prescription decision.
DAC changes how long the molecule stays in circulation. It stands for drug affinity complex, an attachment that binds albumin, a protein in blood. The form without DAC is commonly called modified GRF 1-29 and described as shorter acting, but its precise human clearance time is not established. Any prescription will name the exact form.
The published DAC studies show hormone changes in healthy adults. Two trials used random assignment and an inactive comparison called placebo; a separate study examined growth hormone's bursts of release. These studies did not establish better sleep, muscle gain or recovery, and they cannot settle long-term safety. Their findings also cannot be transferred directly to the form without DAC or to a blend with ipamorelin.
A prescription route adds a clinician and a dispensing pharmacy. Products sold online without a prescription are often labeled for laboratory use, with no reviewing provider or dispensing pharmacy responsible for your care. When visits open, Promise's route will include a licensed provider's decision, pharmacy dispensing and care-team follow-up. That oversight does not fill the gaps in long-term evidence.
Other Hormone & Organ Health options a provider may consider.
Hormone & Organ Health
GH secretagogue for sleep, recovery, and vitality.
Requires an online medical evaluation. Prescribed only when a licensed provider determines it's appropriate.
Hormone & Organ Health
A two-peptide blend pairing a GHRH analog with a selective growth hormone secretagogue, studied for supporting the body's own pulsed release rather than supplying growth hormone.
Requires an online medical evaluation. Prescribed only when a licensed provider determines it's appropriate.
Hormone & Organ Health
A stabilized analog of growth-hormone-releasing hormone, and the most clinically studied peptide in this group — the research has centered on visceral abdominal fat.
Requires an online medical evaluation. Prescribed only when a licensed provider determines it's appropriate.
Type a treatment, a goal, or a question.